Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
 Securities Case - EconoTimes)
NEW YORK, Nov. 10, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 9, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against ProNAi Therapeutics, Inc. (“ProNAi” or the “Company”) (NASDAQ:DNAI). The class action is on behalf of a class consisting of all persons who purchased ProNAi common stock between July 15, 2015 and June 6, 2016, inclusive (the “Class Period”). ProNAi investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3032-pronai-therapeutics-inc-dnai.html.
ProNAi is a clinical stage oncology company with a focus on pioneering a novel class of therapeutics based on its proprietary DNA interference (“DNAi”) technology platform. Until recently, the Company had only one product candidate – PNT2258, which was purportedly designed to target cancers that overexpress B-cell lymphoma such as Hodgkin’s lymphomas and non-Hodgkin lymphoma.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that the Wolverine and Brighton Phase 2 trials of PNT2258 would fail to prove the efficacy and safety of PNT2258 by meeting its primary or secondary endpoints.
On June 6, 2016, the Company issued a press release announcing interim data for the two Phase 2 trials and revealed that PNT2258 had failed to produce sufficient efficacy results to justify its continued clinical development. On this news, the price of ProNAi common stock declined more than 67%.
What You Can Do
If you purchased ProNAi shares, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
